New Milestones and Changing Standards of Care in Early EGFR-Mutated NSCLC

15 Years of Advances in EGFR Mutant Lung CancerПодробнее

ADAURA Trial: Osimertinib for Early Stage EGFR+ NSCLC - 2022 Program: Targeted Therapies ForumПодробнее

New Standard of care Treatment for EGFR Exon 20 Non-small cell Lung Cancer | Dr. Alexander SpiraПодробнее

New standard of care for lung cancer patients with EGFR mutationsПодробнее

Advances in lung cancer treatmentПодробнее

Osimertinib: A potential new standard of care for advanced EGFR-mutated NSCLC | Suresh RamalingamПодробнее

Navigating Rapid Changes in First- and Later-Line Treatment of EGFR-Mutated NSCLCПодробнее

New Standard for Treating Stage 4 EGFR+ NSCLCПодробнее

The Changing Landscape of First Line Treatment for EGFR Mutation-Positive NSCLC.Подробнее

FLAURA study: a new standard of care for patients with EGFR mutated NSCLCПодробнее

Watch Drs. Jones and Pennell discuss the latest in EGFR updates - https://bit.ly/EGFR_2021Подробнее

EGFR Breakout Video Targeted Therapies 2017Подробнее

Consolidation therapy for unresectable stage III EGFR-mutant NSCLCПодробнее

Dr. Wakelee on First-Line Therapy for EGFR-Mutant Lung CancerПодробнее

EGFR Initial Treatment, Acquired Resistance and Q&A with H. Jack West, MD and Helena Yu, MDПодробнее

Case 2: Osimertinib in EGFR-Mutated Lung CancerПодробнее

Marking New Milestones With Immunotherapy in Locally Advanced and Early Lung CancerПодробнее

Multimodal Management of Early-Stage NSCLC: EGFR-Targeted Therapy in Perioperative SettingsПодробнее

Is adjuvant chemotherapy in EGFR mutated NSCLC still required?Подробнее

EGFR-Mutated NSCLC; Where We Are Now?Подробнее